About binimetinib
MEK inhibitor anticancer medicine
Used for
- With encorafenib for unresectable or metastatic melanoma with a BRAF V600 mutation.
- With encorafenib for metastatic non-small-cell lung cancer with a BRAF V600E mutation.
Usual adult dose
45 mg by mouth twice daily with encorafenib; dose may be reduced for side effects.
Common side effects
- Nausea, diarrhea, vomiting, and abdominal pain
- Fatigue and muscle pain
- Rash and swelling
- Raised creatine kinase or liver enzymes
Important warnings
- Can cause serious heart problems; heart function monitoring is needed.
- Can cause eye problems, including retinal detachment.
- Can cause muscle breakdown and bleeding.
- Can harm an unborn baby; effective contraception is recommended during treatment.
Pregnancy
May cause fetal harm. Avoid pregnancy during treatment and for 30 days after the last dose.
Breastfeeding
Do not breastfeed during treatment and for three days after the last dose.
Interactions
- Other medicines that affect CYP enzymes may alter binimetinib levels.
- Warfarin may require closer monitoring of blood clotting.
- Combining with encorafenib increases risk of certain serious side effects.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.